News
06-03-2008, 03:17 AM
At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (Opaxio, CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC).
More... (http://www.news-medical.net/?id=38875)
More... (http://www.news-medical.net/?id=38875)